These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28059608)

  • 1. Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials.
    Catani JPP; Riechelmann RP; Adjemian S; Strauss BE
    Hum Vaccin Immunother; 2017 May; 13(5):1109-1111. PubMed ID: 28059608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy.
    Mandal R; Chan TA
    Cancer Discov; 2016 Jul; 6(7):703-13. PubMed ID: 27107038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
    Paliard X; Rixe O
    Target Oncol; 2019 Dec; 14(6):631-637. PubMed ID: 31595386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
    Yaguchi T; Kawakami Y
    Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of novel immunotherapy targeting cancer immune evasion].
    Tamada K
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New concepts in tumor antigens: their significance in future immunotherapies for tumors.
    Yang F; Yang XF
    Cell Mol Immunol; 2005 Oct; 2(5):331-41. PubMed ID: 16368059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Converging on a Cure: The Roads to Predictive Immunotherapy.
    Stein-O'Brien GL; Le DT; Jaffee EM; Fertig EJ; Zaidi N
    Cancer Discov; 2023 May; 13(5):1053-1057. PubMed ID: 37067199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New principles in tumor antigens and their significance in future immunotherapies for lymphomas and other malignancies--editorial].
    Ke XY; Wang J; Yang XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):419-26. PubMed ID: 16800912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies.
    Xiong J; Wang QQ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):430-439. PubMed ID: 35907687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [At the crossroads of cancer].
    Chouaib S
    Bull Cancer; 2013 Jun; 100(6):569-74. PubMed ID: 23735599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy: accomplishments to date and future promise.
    Helmy KY; Patel SA; Nahas GR; Rameshwar P
    Ther Deliv; 2013 Oct; 4(10):1307-20. PubMed ID: 24116914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte trafficking: Can we bring the fight to the tumor?
    Pachynski R; Nazha J; Kohrt H
    Discov Med; 2016 Mar; 21(115):205-12. PubMed ID: 27115171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tracking cellular and immune therapies in cancer.
    Kurtz DM; Gambhir SS
    Adv Cancer Res; 2014; 124():257-96. PubMed ID: 25287692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivering safer immunotherapies for cancer.
    Milling L; Zhang Y; Irvine DJ
    Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunology and personalized medicine in oncology].
    Zinzindohoué F; Zeitoun G; Berger A; Todosi AM; Marliot F; Lagorce C; Galon J; Pagès F
    Bull Cancer; 2014 Jun; 101 Suppl 1():S12-7. PubMed ID: 24966077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.